Headed to BIO again with more clinical data and understanding of how zelenirstat is affecting multiple validated cancer targets. Looking forward to meeting Pharma companies and investors and fellow attendees. https://lnkd.in/eDJQ_dXM
Pacylex Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
Edmonton, Alberta 805 followers
A new target in cancer care - triggering selective lethality with a new class of drugs.
About us
Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is a small molecule, N-myristoylation inhibitor that selectively kills cultured human leukemia and lymphoma cells ex-vivo, completely shrinks leukemia and lymphoma tumors in mice including tumors from drug resistant patients, and strongly inhibits growth of solid tumors in mice including breast and certain lung cancers. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Since this Phase 1 dose escalation clinical study is nearing the target recommended Phase 2 dose (RP2D), Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.
- Website
-
http://www.pacylex.com
External link for Pacylex Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Edmonton, Alberta
- Type
- Privately Held
- Founded
- 2012
- Specialties
- oncology, pharmaceuticals, personalized medicine, chemotherapy, Leukemia, tumors, and Lymphoma
Locations
-
Primary
Get directions
10180 101 Street
#2600
Edmonton, Alberta T5J 3Y2, CA
Employees at Pacylex Pharmaceuticals, Inc.
-
Luc G. Berthiaume
Professor of Cell Biology University of Alberta
-
Cindy Jacobs Ph.D., M.D.
Director, President & Chief Medical Officer for Achieve Life Sciences, Chairman for Pacylex Pharmaceuticals, Director for HiberCell, & Founder of…
-
John Mackey
Medical Oncologist
-
Mark Huson
Professor at University of Alberta
Updates
-
Pacylex Pharmaceuticals Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in the Journal of Translational Medicine: https://lnkd.in/grFfPK77 The paper describes how inhibiting myristoylation, including with zelenirstat, shuts off energy production by oxidative phosphorylation in mitochondria of cancer cells. It also describes MISS-54, the gene expression set used to predict sensitivity to myristoylation inhibition. This adds another mechanism by which zelenirstat inhibits or kills cancer cells to the growing understanding that inhibiting myristoylation affects key proteins needed for translocation, assembly, and activity of complexes essential for cancer cell growth, proliferation, energy, and survival making zelenirstat potentially a unique broad spectrum agent.
Pacylex Pharmaceuticals Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in the Journal of Translational Medicine
pacylex.reportablenews.com
-
Pacylex CEO is headed to Boston to present zelenirstat for acute myeloid leukemia at the World Orphan Drug Congress https://lnkd.in/g5Vy9ZFz
Pacylex Pharmaceuticals CEO Presents Zelenirstat for Acute Myeloid Leukemia at the World Orphan Drug Congress
pacylex.reportablenews.com
-
Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of zelenirstat in Patients with Refractory Metastatic Colorectal Cancer. https://lnkd.in/giwhTHav
Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of zelenirstat in Patients with Refractory Metastatic Colorectal Cancer
pacylex.reportablenews.com
-
In San Diego to present new data and clinical results at AACR 2024. https://lnkd.in/gVs5CD-J
Pacylex Pharmaceuticals at AACR 2024
pacylex.reportablenews.com
-
Pacylex Pharmaceuticals Reports Zelenirstat Disrupts Oxidative Phosphorylation in Cancer Cells at AACR 2024 - Defines a second potential mechanism which may account for early signs of zelenirstat anti-cancer activity in the Phase 1 study. #AACR2024 #insights #cancer https://lnkd.in/gZkVrxqv.
-
-
Heading to World Orphan Drug Congress in April - zelenirstat has received Orphan Drug Designation for AML. https://lnkd.in/ghRwYqxS
World Orphan Drug Congress USA 2024
terrapinn.com
-
Looking forward to meeting investors in NYC next week: https://lnkd.in/gTyKRSiJ
Pacylex CEO to attend Bio CEO & Investors Conference
pacylex.reportablenews.com
-
Last weekend at the ASCO-GI conference, our CEO had a chance to share the Phase 1 clinical experience with zelenirstat, our first in class, oral, cancer medicine in Phase 2. Take a look. https://lnkd.in/gENDy3ad
Zelenirstat Phase 1 Safety and Efficacy Results
https://www.cincopa.com/
-
Our CEO, Dr. Michael Weickert, will be at ASCO-GI on Saturday, January 20, 2024, to discuss our Phase 1 results. All of the patients still on zelenirstat from our Phase 1 study have GI cancers.
Pacylex Pharmaceuticals Reports Phase 1 Safety and Efficacy Results for Zelenirstat in Colorectal and other Cancers
newsfilecorp.com